Pfizer Inc PFE

$30.67 +0.15 (0.49%)

Valuation

Market cap
173,954,048,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
P/E (trailing)
9.82
P/E (forward)
10.17
Profit margin
12.42%
Debt to equity
0.74

Trading

Volume
49,560,645
Avg volume
31,695,838
Day's range
$30.20 – $31.04
Shares out
5,699,674,000
Stochastic %K
90%
Beta
0.32
Analysts
Hold
Price target
$29.45

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

Benny_Cellura Nov 2, 6:49 PM 0 replies
PFElinepfrenzy1990 Nov 2, 6:38 PM 0 replies
Fliptax Nov 2, 6:06 PM
$PFE 99.9% into this dont ask me why its been a few years 😆
0 replies
biolover Nov 2, 4:37 PM
$VKTX Per $ABBV statement ABBV295 amylin phase 1 b data by year end .. chief MD believes will get better outcome as heavier population. I think he will be disappointed and will be wake up call to CEO who wants to seriously compete in obesity $PFE guided data by year end.. or next year ? Delayed a lot from last year expectation. I doubt to present data this week as may derail SP strength. Amylin based combination destined to failure. Time will show that.
1 replies
Parlandoconme Nov 2, 3:26 PM
$TOMZ Steramist taking over for shit technologies that do not work or ruin expensive equipment. Only a matter of time before this thing rockets up. $AZN $PFE
0 replies
RookyMoves Nov 2, 2:56 PM
$PFE lets see 40+
1 replies
duxxx Nov 2, 1:32 PM 0 replies
Techdamentals Nov 2, 4:35 AM
The six months after a November election are November through April, which is the strongest stretch of the calendar in any year, election or not. An ordinary November to April returns about 7%. The post-midterm figure is 14.4%. Roughly half the famous rally is just the time of year. $PFE reports Tuesday. Video: https://youtu.be/CrL2GMJ44Gw Written version: https://techdamentals.com/newsletter/what-do-midterms-do-to-the-stock-market?ref=st What is it worth? 👇 https://techdamentals.com/v/PFE?ref=st Educational, not advice.
0 replies